Niptify

What does NIPTIFY analyse?

NIPTIFY determines the risk of four of the most common chromosomal diseases in the foetus:
*
Down syndrome
(trisomy 21)
*
Edwards syndrome
(trisomy 18)
*
Patau syndrome
(trisomy 13)
*
Turner syndrome (45,X)
*
If desired, the gender of the foetus can also be determined.

What is NIPTIFY?

The most up-to-date method of screening for chromosomal diseases
*
The most up-to-date method of screening for chromosomal diseases

*
High accuracy helps avoid unnecessary invasive procedures

*
Substantially complements current foetal screening

*
Gives peace of mind to pregnant families

How to test?

The NIPTIFY test is performed from 10+ weeks of pregnancy
*
A doctor, midwife or nurse takes a blood sample
*
The blood sample is delivered to Precision Medicine Laboratory in Tartu, Estonia

*
The results of the test are communicated to the doctor or midwife within ten working days at the latest
*
NIPTIFY results are given and explained to you by your doctor or midwife

We developed NIPTIFY so that a modern medical service would be available to pregnant women as precise and timely as possible.

Why choose NIPTIFY?

SAFE

for both foetus and mother

RELIABLE

Assesses the risk of chromosomal diseases

EARLY

From 10+ weeks of pregnancy

AFFORDABLE

best value for money

  • NIPTIFY is suitable for all pregnant women. The test is taken by pregnant women of all ages who want to test the foetus for possible chromosomal diseases.

  • NIPTIFY is reliable. The test determines the risk of developing chromosomal disease with more than 99% accuracy. In the case of a high-risk result, the doctor will direct the pregnant woman for further studies.

  • NIPTIFY is safe. The test is done on the mother’s blood sample. It does not interfere with the foetal environment and does not endanger the course of pregnancy.

  • NIPTIFY saves time. The test can be done in 10+ weeks of pregnancy. Finding an early foetal chromosome disease gives the woman an informed choice.

  • NIPTIFY tests are conducted in Estonia, EU. The test was developed in collaboration with universities in Estonia and Belgium.

  • Regardless of the NIPTIFY test results, further screening, including ultrasound, should not be abandoned.

The argument “all my three children are healthy” may no longer apply to the fourth.

Partners of NIPTIFY

uz-leuven-logo_ok
tu-kliinikum_ok
tartu-ylikool-logo_ok
idatallinna-keskhaigla-logo_ok
Niptify_lastefond_logo